ClinicalTrials.gg
Active, not recruitingNCT02677922Updated Feb 19, 2026Results posted

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

A Phase 1/2 interventional study of AG-120 and Azacitidine in Leukemia, Myeloid, Acute, sponsored by Celgene. Active, not recruiting at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
50th of 211
130 · median 50
Started
2016
with 6 others
Phase 1/2
23 of 214
4 open now
Primary completion
2018-08
later than 1 of 90 live
Registered
69th of 214
by date
Lead sponsor
12 of 214
Celgene

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 50th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2016, is one of 23 in phase 1/2, reaches primary completion later than 1 of the 90 other live ones, and was the 69th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study are

  1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and,
  2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.
03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • Acute Myeloid Leukemia
  • Leukemia
  • Azacitidine
  • AG-120
  • AG-221
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, primary (ie, de novo) or secondary (progression of Myelodysplastic syndrome [MDS] or myeloproliferative neoplasms [MPN], or therapy-related) acute myeloid leukemia (AML) according to the WHO classification with ≥ 20% leukemic blasts in the bone marrow
  • (ECOG) performance status of 0, 1 or 2
  • Agree to serial bone marrow aspirate/

Exclusion criteria

Exclusion Criteria:

  • Suspected or proven to have acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype
  • AML secondary to chronic myelogenous leukemia (CML)
  • Received a targeted agent against an isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation
  • Has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    AG-120 + Azacitidine

    Drug: AG-120 · Drug: Azacitidine

  • Experimental
    AG-221 + Azacitidine

    Drug: Azacitidine · Drug: AG-221

  • Experimental
    Azacitidine

    Drug: Azacitidine

Interventions

  • DrugAG-120

    Specified dose on specified days

  • Specified dose on specified days

  • DrugAG-221

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)

    Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1.

    Time frame: From first dose to 28 days after first dose

  2. The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)

    The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

    Time frame: From first dose to 28 days after last dose (up to approximately 13 months)

  3. Overall Response Rate: Phase 2 (Randomized Stage)

    The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

    Time frame: From first dose up to approximately 26 months

Secondary outcomes

  1. Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)

    Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

    Time frame: From first dose up to approximately 13 months

  2. Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)

    The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.

    Time frame: From first dose up to approximately 13 months

  3. Event-free Survival (EFS): Phase 2 (Randomized Stage)

    Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.

    Time frame: From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)

  4. The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)

    The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

    Time frame: From first dose to 28 days after last dose (up to approximately 26 months)

  5. Complete Remission Rate: Phase 2 (Randomized Stage)

    The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.

    Time frame: From first dose up to approximately 26 months

  6. Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)

    The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.

    Time frame: From first dose up to approximately 26 months

  7. Duration of Response: Phase 2 (Randomized Stage)

    The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as \> 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.

    Time frame: From first dose up to approximately 26 months

  8. Time to Response: Phase 2 (Randomized Stage)

    Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

    Time frame: From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)

  9. Overall Survival: Phase 2 (Randomized Stage)

    Overall survival (OS) is defined as time from randomization to death due to any cause.

    Time frame: From randomization to date of death (up to approximately 26 months)

  10. One Year Survival Rate: Phase 2 (Randomized Stage)

    The percent of participants alive at 1 year from randomization

    Time frame: From randomization to 1 year after randomization

  11. AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)

    Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.

    Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

  12. Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

    Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data

    Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

  13. Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

    Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

    Time frame: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

  14. AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

    Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.

    Time frame: Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2

  15. AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

    AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule.

    Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

  16. Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

    Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

    Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

  17. Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

    Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

    Time frame: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

  18. Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel.

    Time frame: Baseline and Day 1 Cycle 5

  19. Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.

    Time frame: Baseline and Day 1 Cycle 5

  20. Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)

    The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.

    Time frame: Baseline and Day 1 Cycle 5

  21. Sponsor Derived CR: Phase 2 (Randomized Stage)

    The number of participants with Morphologic Complete Remission (CR) based on laboratory data. CR is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment.

    Time frame: From first dose to end of study

  22. Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)

    The number of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.

    Time frame: From first dose to end of study

  23. Time to Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)

    Time from first dose of study drug to first documented CR/CRh. Morphologic Complete Remission (CR) is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. Morphologic complete remission with partial hematologic recovery (CRh) is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL).

    Time frame: From first dose to end of study

  24. Duration of Sponsor Derived CR/CRh: Phase 2 (Randomized Stage)

    Time from first documented CR/CRh to documented morphologic relapse, PD, or death due to any cause, whichever occurred first. Participants without morphologic relapse, PD, or death due to any cause were censored at the date of the last response assessment. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression (PD) is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.

    Time frame: From first dose to end of study

07

Results

Posted Nov 22, 2022

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestonePhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Started337166833
Completed337166832
Not completed000001
Withdrew: Withdrawal by subject000001
Treatment Period
Participant flow — Treatment Period
MilestonePhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Started337166832
Completed1143211
Not completed223134731
Withdrew: Adverse event001352
Withdrew: Progressive disease110087
Withdrew: Lack of efficacy000116
Withdrew: Withdrawal by subject001355
Withdrew: Transition to commercially available treatment011112
Withdrew: Disease relapse000361
Withdrew: Allogeneic hsct100141
Withdrew: Other reasons000135
Withdrew: Death0000121
Withdrew: Non-compliance with study drug000010
Withdrew: Physician decision000001
Withdrew: Symptomatic deterioration000010

Outcome measures

PrimaryThe Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)

Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1.

Time frame:
From first dose to 28 days after first dose
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)
ParticipantsPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZA
The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)000
PrimaryThe Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)

The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

Time frame:
From first dose to 28 days after last dose (up to approximately 13 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)
ParticipantsPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZA
Participants with at Least One TEAE33716
Participants with at Least One TEAE Related to Study Drug(s)33716
Participants with at Least One Grade 3-4 TEAE33715
Participants with at least One Grade 3-4 TEAE Related to Study Drug(s)22410
Participants with at Least One Grade 5 TEAE0112
Participants with at Least One Grade 5 TEAE Related to Study Drug(s)0000
Participants with at Least One Serious TEAE32411
Participants with at Least One Serious TEAE Related to Study Drug(s)0115
Participants with at Least One TEAE Leading to Discontinuation of Study Drug(s)1014
Participants with at Least One Study Drug Related TEAE Leading to Discontinuation of Study Drug0001
Participants with at Least One TEAE Leading to Dose Reduction of Study Drug(s)1125
Participants with at Least One TEAE Leading to Dose Interruption of Study Drug(s)33211
Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Reduction0115
Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Interruption1228
PrimaryOverall Response Rate: Phase 2 (Randomized Stage)

The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

Time frame:
From first dose up to approximately 26 months
Reported as:
Number · Percent of Participants
Overall Response Rate: Phase 2 (Randomized Stage)
Percent of ParticipantsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Overall Response Rate: Phase 2 (Randomized Stage)73.5 (61.4 to 83.5)36.4 (20.4 to 54.9)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Chi-squared · p = 0.0003 · Odds ratio (or): 4.86 · 95% CI 1.99 to 11.85
SecondaryOverall Response Rate: Phase 1B (Dose Finding and Expansion Stage)

Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

Time frame:
From first dose up to approximately 13 months
Reported as:
Number · Percent of Participants
Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)
Percent of ParticipantsPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZA
Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)66.7 (9.4 to 99.2)66.7 (9.4 to 99.2)100 (59.0 to 100)68.8 (41.3 to 89.0)
SecondarySponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)

The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.

Time frame:
From first dose up to approximately 13 months
Reported as:
Number · Percent of Participants
Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)
Percent of ParticipantsPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZA
Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)66.7 (9.4 to 99.2)66.7 (9.4 to 99.2)71.4 (29.0 to 96.3)62.5 (35.4 to 84.8)
SecondaryEvent-free Survival (EFS): Phase 2 (Randomized Stage)

Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.

Time frame:
From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)
Reported as:
Median · Months
Event-free Survival (EFS): Phase 2 (Randomized Stage)
MonthsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Event-free Survival (EFS): Phase 2 (Randomized Stage)15.9 (13.0 to NA)11.9 (8.2 to 15.5)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Log Rank · p = 0.1083 · Cox proportional hazard: 0.59 · 95% CI 0.30 to 1.13
SecondaryThe Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)

The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

Time frame:
From first dose to 28 days after last dose (up to approximately 26 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)
ParticipantsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Participants with at Least One TEAE6832
Participants with at Least One TEAE Related to Study Drug(s)6226
Participants with at Least One Grade 3-4 TEAE6831
Participants with at least One Grade 3-4 TEAE Related to Study Drug(s)5020
Participants with at Least One Grade 5 TEAE152
Participants with at Least One Grade 5 TEAE Related to Study Drug(s)00
Participants with at Least One Serious TEAE6425
Participants with at Least One Serious TEAE Related to Study Drug(s)2914
SecondaryComplete Remission Rate: Phase 2 (Randomized Stage)

The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.

Time frame:
From first dose up to approximately 26 months
Reported as:
Number · Percent of Participants
Complete Remission Rate: Phase 2 (Randomized Stage)
Percent of ParticipantsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Complete Remission Rate: Phase 2 (Randomized Stage)54.4 (41.9 to 66.5)12.1 (3.4 to 28.2)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Chi-squared · p = <0.001 · Odds ratio (or): 8.65 · 95% CI 2.74 to 27.31
SecondaryHematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)

The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10\^9/L for participants starting with \> 20 X and an increase from \< 20 X 10\^9/L to \> 20 X 10\^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase \> 0.5 X 10\^9/L.

Time frame:
From first dose up to approximately 26 months
Reported as:
Number · Percent of Participants
Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)
Percent of ParticipantsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)70.6 (58.3 to 81.0)57.6 (39.2 to 74.5)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Chi-squared · p = 0.1943 · Odds ratio (or): 1.77 · 95% CI 0.74 to 4.20
SecondaryDuration of Response: Phase 2 (Randomized Stage)

The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as \<5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with \>50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as \> 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease.

Time frame:
From first dose up to approximately 26 months
Reported as:
Median · Months
Duration of Response: Phase 2 (Randomized Stage)
MonthsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Duration of Response: Phase 2 (Randomized Stage)24.1 (10.0 to NA)9.9 (5.5 to 13.6)
SecondaryTime to Response: Phase 2 (Randomized Stage)

Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as \<5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a \>50% decrease in the percentage of BM blasts to 5% to 25%. (\<5% considered if Auer rods are present).

Time frame:
From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)
Reported as:
Mean · Months
Time to Response: Phase 2 (Randomized Stage)
MonthsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Time to Response: Phase 2 (Randomized Stage)3.05 ± 2.5513.42 ± 1.720
SecondaryOverall Survival: Phase 2 (Randomized Stage)

Overall survival (OS) is defined as time from randomization to death due to any cause.

Time frame:
From randomization to date of death (up to approximately 26 months)
Reported as:
Median · Months
Overall Survival: Phase 2 (Randomized Stage)
MonthsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Overall Survival: Phase 2 (Randomized Stage)22.0 (14.6 to NA)22.3 (11.9 to NA)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Log Rank · p = 0.9720 · Cox proportional hazard: 0.99 · 95% CI 0.52 to 1.87Cox proportional hazards regression model
SecondaryOne Year Survival Rate: Phase 2 (Randomized Stage)

The percent of participants alive at 1 year from randomization

Time frame:
From randomization to 1 year after randomization
Reported as:
Number · Percent of Participants
One Year Survival Rate: Phase 2 (Randomized Stage)
Percent of ParticipantsPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
One Year Survival Rate: Phase 2 (Randomized Stage)72.2 (59.6 to 81.5)69.6 (49.6 to 82.9)
Statistical analysis
  • Phase 2 Randomized Stage: AG-221 (100mg) + AZA vs Phase 2 Randomized Stage: AZA Monotherapy · Difference: 2.6 · 95% CI -17.3 to 22.5The CI for the difference was derived using Greenwood's variance estimate.
SecondaryAUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)

Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.

Time frame:
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Reported as:
Mean · (h*ng/mL)
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)
(h*ng/mL)Phase 1b Expansion Stage: AG-120 (500mg) + AZA
CYCLE 1 DAY 131952.4465 ± 16008.00412
CYCLE 2 DAY 144291.5504 ± 18806.17037
SecondaryCmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data

Time frame:
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Reported as:
Mean · (ng/mL)
Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
(ng/mL)Phase 1b Expansion Stage: AG-120 (500mg) + AZA
CYCLE 1 DAY 16058.0 ± 2750.97
CYCLE 2 DAY 16340.7 ± 3191.00
SecondaryTmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

Time frame:
Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2
Reported as:
Median · (h)
Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)
(h)Phase 1b Expansion Stage: AG-120 (500mg) + AZA
CYCLE 1 DAY 13.0000 (0.500 to 8.067)
CYCLE 2 DAY 12.5000 (0.500 to 7.850)
SecondaryAUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule.

Time frame:
Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2
Reported as:
Mean · (h*ng/mL)
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
(h*ng/mL)Phase 2 Randomized Stage: AG-221 (100mg) + AZA
AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)100302.8231 ± 61286.98611
SecondaryAUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule.

Time frame:
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Reported as:
Mean · (h*ng/mL)
AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)
(h*ng/mL)Phase 2 Randomized Stage: AG-221 (100mg) + AZA
AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)285864.2637 ± 190300.31922
SecondaryCmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

Time frame:
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Reported as:
Mean · (ng/mL)
Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
(ng/mL)Phase 2 Randomized Stage: AG-221 (100mg) + AZA
Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)15965.0 ± 9663.47
SecondaryTmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

Time frame:
Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2
Reported as:
Median · (h)
Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)
(h)Phase 2 Randomized Stage: AG-221 (100mg) + AZA
Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)2.5333 (0.000 to 23.917)
SecondaryChange From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel.

Time frame:
Baseline and Day 1 Cycle 5
Reported as:
Mean · Score on a scale
Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)
Score on a scalePhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Global QoL12.2 ± 27.364.9 ± 27.33
Physical functioning1.9 ± 20.66.7 ± 23.57
Role functioning-0.6 ± 29.571.0 ± 30.88
Cognitive functioning-4.8 ± 26.004.9 ± 25.53
Emotional functioning7.7 ± 24.428.8 ± 18.51
Social functioning-6.5 ± 29.526.9 ± 34.89
Fatigue-17.5 ± 33.05-8.5 ± 31.06
Nausea and vomiting-6.0 ± 29.471.0 ± 16.11
Pain-13.1 ± 33.13-4.9 ± 30.48
Dyspnea-27.4 ± 35.20-9.8 ± 28.30
Insomnia-6.0 ± 25.75-13.7 ± 26.51
Appetite loss-7.1 ± 42.90-5.9 ± 35.81
Constipation6.0 ± 32.78-9.8 ± 22.87
Diarrhea-7.1 ± 31.89-5.9 ± 29.43
Financial difficulties8.3 ± 19.51-2.0 ± 34.30
SecondaryChange From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.

Time frame:
Baseline and Day 1 Cycle 5
Reported as:
Mean · Score on a scale
Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)
Score on a scalePhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)0.04 ± 0.2160.02 ± 0.211
SecondaryChange From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)

The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled "the best health you can imagine" and "the worst health you can imagine." The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.

Time frame:
Baseline and Day 1 Cycle 5
Reported as:
Mean · Score on a scale
Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)
Score on a scalePhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)13.00 ± 26.1661.65 ± 27.897
SecondarySponsor Derived CR: Phase 2 (Randomized Stage)

The number of participants with Morphologic Complete Remission (CR) based on laboratory data. CR is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment.

Time frame:
From first dose to end of study

Results for this outcome have not been posted.

SecondarySponsor Derived CR and CRh: Phase 2 (Randomized Phase)

The number of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as Response of bone marrow blast \<5% with absolute neutrophil count (ANC) \> 0.5 × 10\^9/L and platelet \> 50 × 10\^9/L.

Time frame:
From first dose to end of study

Results for this outcome have not been posted.

SecondaryTime to Sponsor Derived CR and CRh: Phase 2 (Randomized Phase)

Time from first dose of study drug to first documented CR/CRh. Morphologic Complete Remission (CR) is defined as as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. Morphologic complete remission with partial hematologic recovery (CRh) is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC \> 500 x 109/L (1,000/μL) \& Platelet count \> 50 x 109/L (100,000/μL).

Time frame:
From first dose to end of study

Results for this outcome have not been posted.

SecondaryDuration of Sponsor Derived CR/CRh: Phase 2 (Randomized Stage)

Time from first documented CR/CRh to documented morphologic relapse, PD, or death due to any cause, whichever occurred first. Participants without morphologic relapse, PD, or death due to any cause were censored at the date of the last response assessment. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression (PD) is defined as a \> 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with \> 70% BM blasts at baseline or the development of new extramedullary disease.

Time frame:
From first dose to end of study

Results for this outcome have not been posted.

Adverse events

Collected over From first dose up to approximately 26 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA1/3 (33.3%)3/3 (100%)3/3 (100%)
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Phase 1b Expansion Stage: AG-120 (500mg) + AZA6/16 (37.5%)11/16 (68.8%)16/16 (100%)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA29/68 (42.6%)64/68 (94.1%)67/68 (98.5%)
Phase 2 Randomized Stage: AZA Monotherapy14/33 (42.4%)25/32 (78.1%)32/32 (100%)
Most frequent serious events
Showing 10 of 151
Most frequent serious events
EventPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
Febrile neutropeniaBlood and lymphatic system disorders1/31/31/77/1626/688/32
ColitisGastrointestinal disorders1/30/30/71/161/680/32
Haemorrhoidal haemorrhageGastrointestinal disorders1/30/30/70/160/680/32
PyrexiaGeneral disorders0/31/30/73/164/682/32
Clostridium difficile colitisInfections and infestations1/30/30/70/160/680/32
Lung infectionInfections and infestations0/31/30/72/167/683/32
PneumoniaInfections and infestations1/31/32/70/167/685/32
Blood bilirubin increasedInvestigations1/31/30/70/163/680/32
Mental status changesPsychiatric disorders0/31/30/70/160/680/32
EmbolismVascular disorders0/31/30/70/160/680/32
Most frequent other events
Showing 10 of 284
Most frequent other events
EventPhase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA Monotherapy
AnaemiaBlood and lymphatic system disorders1/33/33/77/1635/6815/32
Abdominal painGastrointestinal disorders3/31/30/74/1612/685/32
VomitingGastrointestinal disorders1/33/31/79/1633/6811/32
Blood bilirubin increasedInvestigations1/33/31/71/1619/681/32
NauseaGastrointestinal disorders2/32/36/78/1647/6812/32
ThrombocytopeniaBlood and lymphatic system disorders2/32/35/77/1640/6814/32
DiarrhoeaGastrointestinal disorders1/32/35/79/1629/689/32
FatigueGeneral disorders1/31/35/74/1619/688/32
NeutropeniaBlood and lymphatic system disorders0/32/32/73/1631/689/32
ConstipationGastrointestinal disorders2/31/34/77/1631/6815/32

Baseline characteristics

Age, Customized
Age, Customized(Participants)Phase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA MonotherapyTotal
< 6501037112
>= 65-< 751226221447
>= 752057391871
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA MonotherapyTotal
Female2239361163
Male1147322267
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA MonotherapyTotal
Hispanic or Latino0010113
Not Hispanic or Latino336145126103
Unknown or Not Reported000216624
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b Dose-finding Stage: AG-221 (100mg) + AZAPhase 1b Dose-finding Stage: AG-221 (200mg) + AZAPhase 1b Dose-finding Stage: AG-120 (500mg) + AZAPhase 1b Expansion Stage: AG-120 (500mg) + AZAPhase 2 Randomized Stage: AG-221 (100mg) + AZAPhase 2 Randomized Stage: AZA MonotherapyTotal
American Indian or Alaska Native0000000
Asian0001113
Native Hawaiian or Other Pacific Islander0000000
Black or African American1100518
White22713492497
More than one race0000000
Unknown or Not Reported000213722
08

Study locations

49 sites
  • Local Institution - 105
    Duarte, California 91010-301, United States
  • Local Institution - 107
    New Haven, Connecticut 06510, United States
  • Local Institution - 108
    Chicago, Illinois 60611, United States
  • Local Institution - 103
    Chicago, Illinois 60637, United States
  • Local Institution - 102
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Local Institution - 902
    Boston, Massachusetts 02115, United States
  • Local Institution - 106
    New York, New York 10065, United States
  • Local Institution - 110
    Dallas, Texas 75390-85520, United States
  • Local Institution - 178
    Adelaide, South Australia SA 5000, Australia
  • Local Institution - 175
    Melbourne, 3141, Australia
  • Local Institution - 177
    Perth, 6000, Australia
  • Local Institution - UNK-121
    Yvoir, 5530, Belgium
  • Local Institution - 125
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 205
    Lille, 59037, France
  • Local Institution - 206
    Marseille, 13273, France
  • Local Institution - 200
    Paris, 75475, France
  • Local Institution - 204
    Pessac, 33604, France
  • Local Institution - 202
    Pierre-Bénite, 69495, France
  • Local Institution - 203
    Toulouse, 31059, France
  • Local Institution - 201
    Villejuif, 94805, France
  • Local Institution - 227
    Berlin, 12200, Germany
  • Local Institution - 230
    Dresden, 01307, Germany
  • Local Institution - 225
    Ulm, 89081, Germany
  • Local Institution - 253
    Bologna, Emilia-Romagna, 40138, Italy
  • Local Institution - 252
    Florence, 50134, Italy
  • Local Institution - 256
    Genova, 16132, Italy
  • Local Institution - 251
    Orbassano, 10043, Italy
  • Local Institution - 254
    Padova, 35128, Italy
  • Local Institution - 250
    Pesaro, 31122, Italy
  • Local Institution - 255
    Roma, 00189, Italy
  • Local Institution - 277
    Utrecht, 3584 CX, Netherlands
  • Local Institution - 327
    Lisbon, 1169-050, Portugal
  • Local Institution - 351
    Seoul, 135-710, South Korea
  • Local Institution - 350
    Seoul, 138-736, South Korea
  • Local Institution - 379
    Barcelona, 08036, Spain
  • Local Institution - 375
    Barcelona, 08907, Spain
  • Local Institution - 376
    Cáceres, 10005, Spain
  • Local Institution - 378
    Madrid, 28007, Spain
  • Local Institution - 381
    Madrid, 28033, Spain
  • Local Institution - 380
    Málaga, 29010, Spain
  • Local Institution - 377
    Valencia, 46009, Spain
  • Local Institution - UNK-52
    Gothenburg, 413 45, Sweden
  • Local Institution - 403
    Basel, 4031, Switzerland
  • Local Institution - 401
    Zurich, 0, Switzerland
  • Local Institution - 429
    Birmingham, B15 2TH, United Kingdom
  • Local Institution - 427
    Headington, OX3 9DU, United Kingdom
  • Local Institution - 428
    London, SE5 9RS, United Kingdom
  • Local Institution - 430
    Sutton (Surrey), SM2 5PT, United Kingdom
09

References and documents

Publications

  • Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Adv. 2024 May 28;8(10):2509-2519. doi: 10.1182/bloodadvances.2023011914. PubMed 38507688 ↗
  • Woods A, Norsworthy KJ, Wang X, Vallejo J, Chiu Yuen Chow E, Li RJ, Sun J, Charlab R, Jiang X, Pazdur R, Theoret MR, de Claro RA. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clin Cancer Res. 2024 Apr 1;30(7):1226-1231. doi: 10.1158/1078-0432.CCR-23-2234. PubMed 38010220 ↗
  • DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Dohner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18. PubMed 34672961 ↗
  • DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Dohner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29. PubMed 33119479 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Aug 2018, 25 months.

Results were first posted in Nov 2022, 4 years 3 months after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 25 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 9, 2016
StartActual
Jun 3, 2016
Primary completionActual
Aug 2, 2018
CompletionEst.
Sep 30, 2026
Results first posted
Nov 22, 2022
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02677922
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 9, 2016
Start date
Jun 3, 2016
Primary completion
Aug 2, 2018
Completion
Sep 30, 2026 (estimated)
Results posted
Nov 22, 2022
Last update
Feb 19, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion